The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities

키워드

참고문헌 (112)

1. Zimmet P, "Global, societal implications of the diabetes epidemic", Nature, 414, pp.782~787 (2001)
2. Guariguata L, "Global estimates of diabetes prevalence for 2013, projections for 2035", Diabetes Res Clin Pract, 103, pp.137~149 (2013)
3. Roger VL, "Heart disease, stroke statistics--2012 update: a report from the American Heart Association", Circulation, 125, pp.e2~e220 (2012)
4. UK Prospective Diabetes Study(UKPDS)Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
5. Bonora E, "HOMAestimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study", Diabetes Care, 25, pp.1135~1141 (2002)
6. Wajchenberg BL, "beta-cell failure in diabetes, preservation by clinical treatment", Endocr Rev, 28, pp.187~218 (2007)
7. Rothman DL, "31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus", J Clin Invest, 89, pp.1069~1075 (1992)
8. Shulman GI, "Quantitation of muscle glycogen synthesis in normal subjects, subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy", N Engl J Med, 322, pp.223~228 (1990)
9. Hwang JH, "Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study", J Clin Invest, 95, pp.783~787 (1995)
10. Landau BR, "Contributions of gluconeogenesis to glucose production in the fasted state", J Clin Invest, 98, pp.378~385 (1996)
11. DeFronzo RA, "Tripathy, Skeletal muscle insulin resistance is the primary defect in type 2diabetes", Diabetes Care, 32, pp.S157~S163 (2009)
12. DeFronzo RA, "Simonson, Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production, impaired tissue glucose uptake", Metabolism, 38, pp.387~395 (1989)
13. Perry RJ, "Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance, type 2 diabetes", Cell, 160 (2015)
14. Wu L, "Diabetic dyslipidemia", Metabolism, 63, pp.1469~1479 (2014)
15. Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
16. Samuel VT, "Mechanisms for insulin resistance: common threads, missing links", Cell, 148, pp.852~871 (2012)
17. Chaurasia B, "Ceramides-Lipotoxic Inducers of Metabolic Disorders", Trends Endocrinol Metab, 26, pp.538~550 (2015)
18. Samuel VT, "Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease", J Biol Chem, 279, pp.32345~32353 (2004)
19. Magkos F, "Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects", Gastroenterology, 142, pp.1444~1446e2 (2012)
20. Jurczak MJ, "Dissociation of inositol-requiring enzyme(IRE1alpha)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1(XBP1)knock-out mice", J Biol Chem, 287, pp.2558~2567 (2012)
21. Lee SY, "Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis, insulin resistance in mice", Hepatology, 62, pp.135~146 (2015)
22. Haus JM, "Plasma ceramides are elevated in obese subjects with type 2 diabetes, correlate with the severity of insulin resistance", Diabetes, 58, pp.337~343 (2009)
23. Adams JM 2nd, "Ceramide content is increased in skeletal muscle from obese insulin-resistant humans", Diabetes, 53, pp.25~31 (2004)
24. Mooradian AD, "Dyslipidemia in type 2 diabetes mellitus", Nat Clin Pract Endocrinol Metab, 5, pp.150~159 (2009)
25. Semple RK, "Postreceptor insulin resistance contributes to human dyslipidemia, hepatic steatosis", J Clin Invest, 119, pp.315~322 (2009)
26. Rader DJ, "Effect of insulin resistance, dyslipidemia, , intra-abdominal adiposity on the development of cardiovascular disease, diabetes mellitus", Am J Med, 120, pp.S12~S18 (2007)
27. Adiels M, "Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome", Arterioscler Thromb Vasc Biol, 28, pp.1225~1236 (2008)
28. Bang KB, "Comorbidities, Metabolic Derangement of NAFLD", J Lifestyle Med, 5, pp.7~13 (2015)
29. Koo SH, "Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis", Clin Mol Hepatol, 19, pp.210~215 (2013)
30. Athyros VG, "Cardiovascular risk across the histological spectrum, the clinical manifestations of non-alcoholic fatty liver disease: An update", World J Gastroenterol, 21, pp.6820~6834 (2015)
31. Williams CD, "Prevalence of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound, liver biopsy: a prospective study", Gastroenterology, 140, pp.124~131 (2011)
32. American Diabetes Association, "Standards of medical care in diabetes--2009", Diabetes Care, 32, pp.S13~S61 (2009)
33. Klip A, "Cellular mechanism of action of metformin", Diabetes Care, 13, pp.696~704 (1990)
34. Stumvoll M, "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus", N Engl J Med, 333, pp.550~554 (1995)
35. Kim YD, "Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP", Diabetes, 57, pp.306~314 (2008)
36. Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action", J Clin Invest, 108, pp.1167~1174 (2001)
37. Wulffelé MG, "The effect of metformin on blood pressure, plasma cholesterol, triglycerides in type 2diabetes mellitus: a systematic review", J Intern Med, 256, pp.1~14 (2004)
38. Shields WW, "The Effect of Metformin, Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance, Nonalcoholic Steatohepatitis (NASH): A Pilot Trial", Therap Adv Gastroenterol, 2, pp.157~163 (2009)
39. Madiraju AK, "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase", Nature, 510, pp.542~546 (2014)
40. -thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent, "Diabetes", 1983, 804~810
41. Soccio RE, "Thiazolidinediones, the promise of insulin sensitization in type 2diabetes", Cell Metab, 20, pp.573~591 (2014)
42. Chao L, "Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones", J Clin Invest, 106, pp.1221~1228 (2000)
43. Ohno H, "PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein", Cell Metab, 15, pp.395~404 (2012)
44. Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy", N Engl J Med, 355, pp.2427~2443 (2006)
45. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
46. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
47. Ratziu V, "Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial", Gastroenterology, 135, pp.100~110 (2008)
48. Cariou B, "Thiazolidinediones, PPARgamma agonists: time for a reassessment", Trends Endocrinol Metab, 23, pp.205~215 (2012)
49. Gray LR, "Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis, Whole-Body Glucose Homeostasis", Cell Metab, 22, pp.669~681 (2015)
50. Colca JR, "Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer", Clin Pharmacol Ther, 93, pp.352~359 (2013)
51. Kramer W, "Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells", Horm Metab Res, 28, pp.464~468 (1996)
52. DeFronzo RA, "Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals", Diabetes Care, 7, pp.72~80 (1984)
53. Taskinen MR, "Effects of NIDDM on very-low-density lipoprotein triglyceride, apolipoprotein B metabolism. Studies before, after sulfonylurea therapy", Diabetes, 35, pp.1268~1277 (1986)
54. Howard BV, "Effect of sulfonylurea therapy on plasma lipids, high-density lipoprotein composition in non-insulin-dependent diabetes mellitus", Am J Med, 79, pp.78~85 (1985)
55. Monami M, "Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials", Adv Ther, 29, pp.736~746 (2012)
56. Gerstein HC, "Basal insulin, cardiovascular, other outcomes in dysglycemia", N Engl J Med, 367, pp.319~328 (2012)
57. Ben-Shlomo S, "Glucagonlike peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase", J Hepatol, 54, pp.1214~1223 (2011)
58. Ding X, "Exendin-4, a glucagon-like protein-1(GLP-1)receptor agonist, reverses hepatic steatosis in ob", ob mice, 2006, pp.43, 173~181
59. Mells JE, "Glp-1 analog, liraglutide, ameliorates hepatic steatosis, cardiac hypertrophy in C57BL", 6J mice fed a Western diet, 2012, pp.302, G225~235
60. Armstrong MJ, "Liraglutide safety, efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study", Lancet (2015)
61. Wang XC, "Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease, inflammation", World J Gastroenterol, 20, pp.14821~14830 (2014)
62. Aroor AR, "Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis, insulin resistance through hepatic lipid remodeling, modulation of hepatic mitochondrial function", Diabetes, 64, pp.1988~2001 (2015)
63. Kato H, "Effect of sitagliptin on intrahepatic lipid content, body fat in patients with type 2 diabetes", Diabetes Res Clin Pract, 109, pp.199~205 (2015)
64. Macauley M, "Effect of vildagliptin on hepatic steatosis", J Clin Endocrinol Metab, 100, pp.1578~1585 (2015)
65. Scirica BM, "Saxagliptin, cardiovascular outcomes in patients with type 2diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
66. Ferrannini E, "Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients", J Clin Invest, 124, pp.499~508 (2014)
67. Bolinder J, "Dapagliflozin maintains glycaemic control while reducing weight, body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin", Diabetes Obes Metab, 16, pp.159~169 (2014)
68. Yokono M, "SGLT2selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats", Eur J Pharmacol, 727, pp.66~74 (2014)
69. Neumiller JJ, "Empagliflozin : a new sodium-glucose co-transporter 2(SGLT2)inhibitor for the treatment of type 2 diabetes", Drugs Context, 3, pp.212262~ (2014)
70. Bode B, "Long-term efficacy, safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes", Diabetes Obes Metab, 17, pp.294~303 (2015)
71. Zinman B, "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2Diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
72. Pfefferkorn JA, "Strategies for the design of hepatoselective glucokinase activators to treat type 2diabetes", Expert Opin Drug Discov, 8, pp.319~330 (2013)
73. Sammons MF, "Recent progress in the development of small-molecule glucagon receptor antagonists", Bioorg Med Chem Lett, 25, pp.4057~4064 (2015)
74. Erion DM, "The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats", PLoS One, 9, pp.e97139~ (2014)
75. Guan HP, "Glucagon receptor antagonism induces increased cholesterol absorption", J Lipid Res, 56, pp.2183~2195 (2015)
76. Sazonov V, "Effects of niacin on the incidence of new onset diabetes, cardiovascular events in patients with normoglycaemia, impaired fasting glucose", Int J Clin Pract, 67, pp.297~302 (2013)
77. McKenney J, "New perspectives on the use of niacin in the treatment of lipid disorders", Arch Intern Med, 164, pp.697~705 (2004)
78. Capuzzi DM, "Niacin dosing: relationship to benefits, adverse effects", Curr Atheroscler Rep, 2, pp.64~71 (2000)
79. Drood JM, "Nicotinic-Acid for the Treatment of Hyperlipoproteinemia", J Clin Pharmacol, 31, pp.641~650 (1991)
80. Elam MB, "Effect of niacin on lipid, lipoprotein levels, glycemic control in patients with diabetes, peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial", JAMA, 284, pp.1263~1270 (2000)
81. Downs JR, "Primary prevention of acute coronary events with lovastatin in men, women with average cholesterol levels: results of AFCAPS", TexCAPS. Air Force, JAMA, pp.1998, 279[DOI]
82. Shepherd J, "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group", N Engl J Med, 333, pp.1301~1307 (1995)
83. McFarlane SI, "Clinical review 145: Pleiotropic effects of statins:lipid reduction, beyond", J Clin Endocrinol Metab, 87, pp.1451~1458 (2002)
84. Sugiyama S, "Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance, coronary artery disease", Atherosclerosis, 194, pp.e43~e51 (2007)
85. Preiss D, "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis", JAMA, 305, pp.2556~2564 (2011)
86. Sattar N, "Statins, risk of incident diabetes: a collaborative meta-analysis of randomised statin trials", Lancet, 375, pp.735~742 (2010)
87. Mullard A, "Cholesterol-lowering blockbuster candidates speed into Phase III trials", Nat Rev Drug Discov, 11, pp.817~819 (2012)
88. Roth EM, "Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial", Int J Cardiol, 176, pp.55~61 (2014)
89. Okamoto H, "A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits", Nature, 406, pp.203~207 (2000)
90. de Grooth GJ, "Efficacy, safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans-A randomized phase II dose-response study", Circulation, 105, pp.2159~2165 (2002)
91. Nicholls SJ, "Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL, LDL Cholesterol A Randomized Controlled Trial", JAMA, 306, pp.2099~2109 (2011)
92. Barter PJ, "Effect of torcetrapib on glucose, insulin, , hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events(ILLUMINATE)trial", Circulation, 124, pp.555~562 (2011)
93. Kharitonenkov A, "FGF21 : a novel prospect for the treatment of metabolic diseases", Curr Opin Investig Drugs, 10, pp.359~364 (2009)
94. Lin Z, "Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis, insulin sensitivity in mice", Cell Metab, 17, pp.779~789 (2013)
95. Bernardo B, "FGF21does not require interscapular brown adipose tissue, improves liver metabolic profile in animal models of obesity, insulin-resistance", Sci Rep, 5, pp.11382~ (2015)
96. Gaich G, "The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes", Cell Metab, 18, pp.333~340 (2013)
97. Petersen KF, "Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease", N Engl J Med, 362, pp.1082~1089 (2010)
98. Petersen KF, "Increased prevalence of insulin resistance, nonalcoholic fatty liver disease in Asian-Indian men", Proc Natl Acad Sci U S A, 103, pp.18273~18277 (2006)
99. Lee HY, "Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis, hepatic insulin resistance", Hepatology, 54, pp.1650~1660 (2011)
100. Jørgensen AB, "Loss-of-function mutations in APOC3, risk of ischemic vascular disease", N Engl J Med, 371, pp.32~41 (2014)
101. Crosby J, "Loss-of-function mutations in APOC3, triglycerides, , coronary disease", N Engl J Med, 371, pp.22~31 (2014)
102. Timpson NJ, "A rare variant in APOC3 is associated with plasma triglyceride, VLDL levels in Europeans", Nat Commun, 5, pp.4871~ (2014)
103. Gaudet D, "Targeting APOC3 in the familial chylomicronemia syndrome", N Engl J Med, 371, pp.2200~2206 (2014)
104. Cao J, "Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases", J Biol Chem, 286, pp.41838~41851 (2011)
105. Chen HC, "Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice", Arterioscler Thromb Vasc Biol, 25, pp.482~486 (2005)
106. Yamamoto T, "Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis,, lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets", Eur J Pharmacol, 640, pp.243~249 (2010)
107. Choi CS, "Suppression of diacylglycerol acyltransferase-2(DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis, insulin resistance", J Biol Chem, 282, pp.22678~22688 (2007)
108. Denison H, "Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study", Diabetes Obes Metab, 15, pp.136~143 (2013)
109. Wierzbicki AS, "New lipid-lowering drugs: an update", Int J Clin Pract, 66, pp.270~280 (2012)
110. Lee YJ, "Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1(MGAT1)expression is responsible for the lipid accumulation in diet-induced hepatic steatosis", Proc Natl Acad Sci U S A, 109, pp.13656~13661 (2012)
111. Hall AM, "Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance, hepatic insulin signaling in obese mice", Diabetes, 63, pp.2284~2296 (2014)
112. Hall AM, "Evidence for regulated monoacylglycerol acyltransferase expression, activity in human liver", J Lipid Res, 53, pp.990~999 (2012)

관련 논문AI추천